
Biocept BIOC
Quartalsbericht 2023-Q2
hinzugefügt 14.08.2023
Biocept Betriebsaufwand 2011-2026 | BIOC
Betriebsaufwand Jährlich Biocept
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 21.6 M | 17.6 M | 17.5 M | 16.9 M | 14.3 M | 12.4 M | 11.8 M | 5.75 M | 9.41 M | 12.3 M |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 21.6 M | 5.75 M | 14 M |
Betriebsaufwand anderer Aktien in der Diagnostik & Forschung
| Name | Betriebsaufwand | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
58 M | - | -6.23 % | $ 30.6 M | ||
|
Burning Rock Biotech Limited
BNR
|
726 M | $ 19.89 | 10.93 % | $ 211 M | ||
|
Agilent Technologies
A
|
1.99 B | $ 120.39 | 2.46 % | $ 36.6 B | ||
|
Aspira Women's Health
AWH
|
13.8 M | - | -6.19 % | $ 10.5 M | ||
|
Check-Cap Ltd.
CHEK
|
14.1 M | - | - | $ 9.42 M | ||
|
Chembio Diagnostics
CEMI
|
28.5 M | - | 0.22 % | $ 16.8 M | ||
|
CareDx, Inc
CDNA
|
411 M | $ 17.63 | 4.75 % | $ 939 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
59.4 M | - | - | $ 562 M | ||
|
DermTech
DMTK
|
104 M | - | -11.32 % | $ 2.94 M | ||
|
Akumin
AKU
|
778 M | - | -17.87 % | $ 25.9 M | ||
|
Enzo Biochem
ENZ
|
47.4 M | - | -8.98 % | $ 14.8 K | ||
|
Co-Diagnostics
CODX
|
50.6 M | $ 1.38 | -4.83 % | $ 1.84 M | ||
|
Exact Sciences Corporation
EXAS
|
2.47 B | - | - | $ 19.8 B | ||
|
Accelerate Diagnostics
AXDX
|
77.2 M | - | -61.36 % | $ 2.46 M | ||
|
Castle Biosciences
CSTL
|
59.5 M | $ 24.37 | 3.57 % | $ 677 M | ||
|
Global Cord Blood Corporation
CO
|
451 M | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
134 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
5.91 M | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
983 M | - | 0.12 % | $ 80.1 M | ||
|
Charles River Laboratories International
CRL
|
607 M | $ 179.31 | 0.54 % | $ 8.89 B | ||
|
PRA Health Sciences, Inc.
PRAH
|
585 M | - | - | $ 10.7 B | ||
|
Interpace Biosciences
IDXG
|
20 M | $ 2.2 | - | $ 9.73 M | ||
|
Danaher Corporation
DHR
|
6.71 B | $ 198.61 | 1.4 % | $ 142 B | ||
|
Heska Corporation
HSKA
|
131 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
24.1 M | - | -20.0 % | $ 1.06 M | ||
|
Illumina
ILMN
|
3.69 B | $ 130.32 | 2.65 % | $ 20.7 B | ||
|
Medpace Holdings
MEDP
|
118 M | $ 520.0 | 3.74 % | $ 15 B | ||
|
Fulgent Genetics
FLGT
|
181 M | $ 16.02 | 4.71 % | $ 484 M | ||
|
Koninklijke Philips N.V.
PHG
|
7.12 B | $ 29.09 | 1.89 % | $ 20 B | ||
|
Motus GI Holdings
MOTS
|
18.6 M | - | -34.28 % | $ 263 K | ||
|
Guardant Health
GH
|
226 M | $ 86.4 | 5.1 % | $ 10.8 B | ||
|
QIAGEN N.V.
QGEN
|
821 M | - | - | $ 10.6 B | ||
|
Myriad Genetics
MYGN
|
964 M | $ 4.91 | 6.97 % | $ 455 M | ||
|
Anixa Biosciences
ANIX
|
9.98 M | $ 2.88 | 1.05 % | $ 93.5 K | ||
|
Biomerica
BMRA
|
5.64 M | $ 2.1 | 0.96 % | $ 4.82 M | ||
|
Senseonics Holdings
SENS
|
61.8 M | $ 6.75 | 0.45 % | $ 282 M | ||
|
ICON Public Limited Company
ICLR
|
408 M | $ 113.06 | 2.44 % | $ 9.33 B | ||
|
NeoGenomics
NEO
|
430 M | $ 8.35 | 4.38 % | $ 1.07 B | ||
|
Laboratory Corporation of America Holdings
LH
|
1.87 B | $ 268.87 | 1.78 % | $ 22.4 B | ||
|
Celcuity
CELC
|
172 M | $ 120.85 | 0.37 % | $ 5.65 B | ||
|
Neogen Corporation
NEOG
|
1.48 B | $ 9.61 | 5.14 % | $ 2.08 B | ||
|
Lantheus Holdings
LNTH
|
123 M | $ 82.74 | 1.31 % | $ 5.58 B | ||
|
Quest Diagnostics Incorporated
DGX
|
1.46 B | $ 194.16 | 0.65 % | $ 21.6 B | ||
|
Natera
NTRA
|
258 M | $ 214.64 | 6.31 % | $ 21.1 B | ||
|
ENDRA Life Sciences
NDRA
|
5.76 M | $ 4.96 | -4.43 % | $ 3.9 M | ||
|
Invitae Corporation
NVTA
|
343 M | - | - | $ 21.2 M | ||
|
National Research Corporation
NRC
|
38.5 M | $ 17.04 | 1.34 % | $ 381 M | ||
|
Organovo Holdings
ONVO
|
23.3 M | - | -2.3 % | $ 19.4 M | ||
|
OpGen
OPGN
|
21.9 M | - | -16.95 % | $ 1.54 M |